Daylight photodynamic therapy with methyl aminolevulinate for the treatment of actinic keratoses of the forearms

Fai, Dario; Fai, Carlotta; Cassano, Nicoletta; Veña, Gino Antonio

doi:10.23736/s0392-0488.18.05910-2

Cited by 6 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few studies (comparing daylight to red light) involved follow-ups for up to 6 or even 12 months. 2,[11][12][13] Our study showed that the response was maintained at 6 months, with a reduction of more than 90% when using DL-PDT. A systematic review was performed in 2019 and only three studies on AKs reported a 12month long-term efficacy of MAL DL-PDT, 12,14,15 but only one study was compared to red light in AKs.…”

Section: Discussionsupporting

confidence: 50%

“…A few studies (comparing daylight to red light) involved follow‐ups for up to 6 or even 12 months . Our study showed that the response was maintained at 6 months, with a reduction of more than 90% when using DL‐PDT.…”

Section: Discussionmentioning

confidence: 54%

“…Several randomized studies have proven the non‐inferiority of DL‐PDT vs. PDT with red light . This is the first randomized study comparing daylight exposure with blue light exposure in PDT for the treatment of AKs.…”

Section: Discussionmentioning

confidence: 94%

“…Several randomized studies have proven the non-inferiority of DL-PDT vs. PDT with red light. 2,3,[9][10][11][12][13] This is the first randomized study comparing daylight exposure with blue light exposure in PDT for the treatment of AKs. No statistical difference in terms of efficacy was found between DL-PDT and c-PDT, with a mean difference of cleared AKs of 0.5 AE 6.2 (P = 0.8460) between the two sides.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra‐individual study

Assikar

Labrunie

Kérob

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background We know the efficacy of daylight phototherapy dynamic (DL-PDT) in the treatment of actinic keratosis (AK). But the almost studies have compared daylight with red light using methyl aminolevulinate cream and not with blue light. PDT with blue light is another conventional PDT that is effective in the treatment of AKs. Objectives The aim of this study is to assess the efficacy and the safety of DL-PDT vs. PDT in blue light in the treatment of AKs. Methods This randomized, controlled, intra-individual efficacy and safety study enrolled 26 subjects. AKs on the face/ scalp were treated once, with DL-PDT on one side and c-PDT on the contralateral side. Primary endpoints for DL-PDT at week 12 were efficacy with clearance of AKs and safety with assessment of pain. Lesions with complete response 12 weeks after one treatment session were followed until week 24. Results More than 1000 AK were studied. At week 12, the raw number of disappeared AK lesions at 3-month followup was 19.6 (AE6.0) for DL-PDT and 20.0 (AE6.9) for c-PDT with P = 0.8460 (90.5% vs. 94.2% of AK disappearance, respectively). The response was maintained at 6 months (90.0% and 94.6% of AK reduction, respectively). DL-PDT was nearly painless than c-PDT with light blue: 1.2 vs. 5.1, respectively (P < 0.0001). Conclusions Daylight-PDT seems as effective as c-PDT with light blue and DL-PDT is less painful. The response of DL-PDT was sustainable until 6 months.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra‐individual study

Assikar

Labrunie

Kérob

et al. 2020

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…DL-PDT has proven to be an effective therapy for mild-tomoderate AKs; however, three studies showed that the clinical response of thick AKs and BCCs is limited. [100][101][102] This variation in therapeutic efficacy may be aided by the physical properties of PpIX absorption, as 90% of PpIX absorption happens in the blue light region (400-430 nm); however, such light has limited tissue penetration (< 1 mm). Comparatively, only 3% of PpIX absorption happens in the orange-red light region (600-700 nm), while its skin penetration increases to around 10 mm.…”

Section: Alternative Light Sourcesmentioning

confidence: 99%

Gain with no pain? Pain management in dermatological photodynamic therapy

et al. 2017

View full text Add to dashboard Cite

Pain during photodynamic therapy (PDT) is the main limiting adverse effect in its use in dermatology. Given its multifactorial nature, we reviewed both intrinsic and extrinsic factors that are involved in PDT pain. We propose a threshold theory for pain experience in PDT: it correlates positively with fluence rate and dose below a certain threshold (rate of ~60 mW cm , dose of ~50 J cm ); when the threshold is surpassed, pain intensity saturates. Additionally, we carefully compared recent updates on pain management strategies and we suggest that cold-air analgesia and low-irradiance light sources (such as variable pulsed light and daylight PDT) represent the current best analgesic options. Finally, we discuss the possible mechanisms of pain experience during PDT. Reactive oxygen species, transient receptor potential channels and inflammatory responses are key mediators in pain. Further investigation into these pathways should help with the development of more effective analgesic strategies. Taking these points together, for pain management in PDT, an individualized plan of analgesia is possible.

show abstract

lncRNA TINCR participates in ALA‐PDT‐induced apoptosis and autophagy in cutaneous squamous cell carcinoma

Zhang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

This study aims to investigate whether terminal differentiation-induced ncRNA (TINCR) has an effect on apoptosis and autophagy induced by ALA-PDT in cutaneous squamous cell carcinoma (CSCC). A431 cells were treated with 5-aminolevulinic acid (ALA) solution at different concentrations and for different duration time. A431 cell viability was detected by Cell Counting Kit-8 (CCK-8) assay, relative TINCR messenger RNA expression was detected by quantitative reverse-transcription polymerase chain reaction (qRT-PCR). A431 cell apoptosis was examined by flow cytometry. Relative apoptosis/autophagyrelated protein expression was analyzed by Western blot analysis. The effect of TINCR on cell autophagy was detected by RFP-LC3 immunofluorescence assay. Reactive oxygen species concentration was detected by 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA) fluorescent probe. Relative expressions of ERK1/2 and specificity protein 3 (Sp3) in A43 cells were detected by Western blot analysis and qRT-PCR. Sp3 binding sites were analyzed by ChIP-qPCR. The relative transcription activity was measured with luciferase reporter assay. ALA-PDT treatment at 3.2 mmol/L for 120 minutes significantly promoted TINCR expression in CSCC A431 cells, and TINCR promoted ALA-PDT-induced apoptosis and cell autophagy. Furthermore, ALA-PDT promoted TINCR expression through ERK1/2-SP3 pathway. Sp3 promoted TINCR transcription by binding TINCR promoters. Our data indicated that TINCR involves in ALA-PDT-induced apoptosis and autophagy in CSCC. K E Y W O R D S apoptosis, autophagy, ERK1/2-Sp3 pathway, terminal differentiation-induced ncRNA J Cell Biochem. 2019;120:13893-13902.wileyonlinelibrary.com/journal/jcb

show abstract

Daylight photodynamic therapy with methyl aminolevulinate for the treatment of actinic keratoses of the forearms

Cited by 6 publications

References 4 publications

Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra‐individual study

Daylight photodynamic therapy with methyl aminolevulinate cream is as effective as conventional photodynamic therapy with blue light in the treatment of actinic keratosis: a controlled randomized intra‐individual study

Gain with no pain? Pain management in dermatological photodynamic therapy

lncRNA TINCR participates in ALA‐PDT‐induced apoptosis and autophagy in cutaneous squamous cell carcinoma

Contact Info

Product

Resources

About